US FDA Partially Holds Cancer Drug Trial of Blueprint Medicines
On February 8, 2023, the US Food and Drug Administration (FDA) informed Blueprint Medicines Corporation that the Phase 1/2 VELA trial of BLU-222 had been placed on partial clinical hold due to the presence of visual adverse events (AEs) in a small number of patients. According to the study, the drug is being administered to […]
Continue Reading